
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences is set to potentially disrupt the cell and gene therapy industry with its proprietary gene circuit platform and its lead candidate SENTI-202 showing promising results in clinical trials. In addition, its identification of a donor phenotype that correlates with improved outcomes could further boost efficacy and increase adoption of its therapy. However, there are risks to consider, such as regulatory uncertainties and the potential need for additional financing which could result in share dilution for shareholders.
Bears say
Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies for cancers using its gene circuit platform, with its leading candidate SENTI-202 targeting CD33 and FLT3 for Acute Myeloid Leukemia (AML). Their recent financing deal raises concern for future dilution, while their logic-gated off-the-shelf CAR-NK cell therapy's complicated manufacturing and significant competition in the cell therapy space present challenges to their promising initial data for SENTI-202 and their overall potential commercial success, leading to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares